You are here: Industry Insights > X

News List

Now and Next in Type 2 Diabetes Suzanne Elvidge
May 06, 2025
Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
Pharmacovigilance Regulations and Application: Safeguarding Drug Safety in a Complex Global Environment David Orchard-Webb
May 06, 2025
In a pharmaceutical world characterized by rapid innovation and international marketplaces, safeguarding medication safety beyond commercialization has never been more important.
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress ACN Newswire
April 25, 2025
HighTide Therapeutics announced that it will present at the EASL Congress 2025. The presentations include New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010).
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field? Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
The Role of Exosomes in Drug Delivery: A Natural Alternative to Synthetic Nanocarriers? Nurah Ekhlaque
April 09, 2025
Explore how exosome-based nanocarriers are shaping precision medicine by supporting targeted drug delivery in cancer and neurodegenerative diseases, with potential for reduced side effects.
Falling off the Patent Cliff: Patent Expirations in 2025 and Onwards Suzanne Elvidge
March 31, 2025
In the early 2010s, a new phenomenon hit the pharmaceutical industry – the patent cliff.
TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients' Access to Life-Changing Medicines PR Newswire
February 12, 2025
Partnership taps real-world data to accelerate clinical trials and drug development in Japan.
Improving the Patient Experience: Developing Patient-centric Dosage Forms Suzanne Elvidge
February 05, 2025
Medication non - adherence impacts many. Patient - centric drug design via simplifying dose, ease - of - taking, better packaging, and 3D - printing can boost adherence.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.